Short term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate cancer

Basit Öğe Kaydı
dc.authoridÇinçin, Altuğ/0000-0002-5925-596X
dc.authorwosidÇinçin, Altuğ/AAW-7556-2021
dc.contributor.authorAgirbasli, Mehmet
dc.contributor.authorBaykan, Oytun A.
dc.contributor.authorTekin, Ali
dc.contributor.authorSengor, Feridun
dc.contributor.authorCincin, Altug A.
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorVaughan, Douglas E.
dc.date.accessioned2024-06-12T11:16:10Z
dc.date.available2024-06-12T11:16:10Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Gonadotropin releasing hormone (GnRH) agonists are the cornerstone of metastatic prostate cancer treatment. Cardiovascular effects of GnRH agonists are unclear. In this study, we investigated the short term effects of GnRH agonists on plasma fibrinolytic parameters in patients with metastatic prostate cancer. Methods Eleven patients (mean age 69.3 +/- A 6.5) with metastatic prostate cancer and a clinical indication for GnRH agonist therapy were selected. Plasma plasminogen activator inhibitor (PAI-1) antigen (Ag), tissue plasminogen activator (t-PA) Ag and thrombin-activatable fibrinolysis inhibitor (TAFI) activity levels were measured at baseline and at 4 weeks after the first dose of GnRH agonist, Goserelin Acetate (Zoladex(A (R)), subcutaneous administration, 10.8 mg). Results Serum prostate specific antigen (PSA) levels significantly decreased from 36.6 +/- A 19.3 to 1.1 +/- A 0.3 ng/ml after Goserelin acetate treatment (P = 0.005). Significant changes occurred in the fibrinolytic parameters. GnRH agonists decreased plasma t-PA Ag levels (16.3 +/- A 4.9 vs. 12.2 +/- A 2.8 ng/ml, P = 0.047) and increased PAI-1/t-PA molar ratio (4.8 +/- A 3.6 vs. 6.6 +/- A 3.4, P = 0.16), on the other hand, plasma PAI-1 Ag (59.0 +/- A 48.5 vs. 56.4 +/- A 30.5 ng/ml, P = 0.8), and TAFI levels (130.6 +/- A 9.5 vs. 124.2 +/- A 26.5% activity, P = 0.3) did not change significantly. Conclusion This study provides evidence that GnRH agonists may inhibit fibrinolytic system by decreasing t-PA levels.en_US
dc.identifier.doi10.1007/s11239-007-0188-4
dc.identifier.endpage174en_US
dc.identifier.issn0929-5305
dc.identifier.issue2en_US
dc.identifier.pmid18183354en_US
dc.identifier.scopus2-s2.0-62149085592en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage172en_US
dc.identifier.urihttps://doi.org/10.1007/s11239-007-0188-4
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24207
dc.identifier.volume27en_US
dc.identifier.wosWOS:000263877400009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Thrombosis And Thrombolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTestosteroneen_US
dc.subjectGnrh Agonistsen_US
dc.subjectPlasma Fibrinolytic Balanceen_US
dc.subjectPAI-1en_US
dc.subjectT-PAen_US
dc.subjectTAFIen_US
dc.subjectTissue-Plasminogen-Activatoren_US
dc.subjectEndothelial-Cellsen_US
dc.subjectTestosteroneen_US
dc.subjectDiseaseen_US
dc.subjectRisken_US
dc.titleShort term effects of GnRH agonists on plasma fibrinolytic balance in patients with advanced prostate canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu